|
Book Title: Treating and Preventing Adolescent Mental Health Disorders
> pp. [663]
UNDEFINED: AUTHORS
Treating and Preventing Adolescent Mental Health Disorders
Print ISBN 9780195173642, 2005
pp. [663]
ican Academy Child and Adolescent Psychiatry, 37, 221–227.
Kwon, J. S., O'Donnell, B. F., Wallenstein, G. V., Greene, R. W., Hirayasu, Y., Nestor, P. G., et al. (1999). Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Archives of General Psychiatry, 56, 1001–1005.
Lambe, E. K., Krimer, L. S., & Goldman-Rakic, P. S. (2000). Differential postnatal development of catecholamine and serotonin inputs to identified neurons in prefrontal cortex of rhesus monkey. Journal of Neuroscience, 20, 8780–8787.
Lammers, C. H., Garcia-Borreguero, D., Schmider, J., Gotthardt, U., Dettling, M., Holsboer, F., et al. (1995). Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls. Biological Psychiatry, 38, 803–807.
Lane, A., Kinsella, A., Murphy, P., Byrne, M., Keenan, J., Colgan, K., et al. (1997). The anthropometric assessment of dysmorphic features in schizophrenia as an index of its developmental origins. Psychological Medicine, 27, 1155–1164.
Lay, B., Blanz, B., Hartmann, M., & Schmidt, M. H. (2000). The psychosocial outcome of adolescent-onset schizophrenia: A 12-year follow-up. Schizophrenia Bulletin, 26, 801–816.
Leff, J., Kuipers, L., Berkowitz, R., Eberlein-Vries, R., & Sturgeon, D. (1982). A controlled trial of social intervention in the families of schizophrenic patients. British Journal of Psychiatry, 141, 121–134.
Lehman, A. F., & Steinwachs, D. M. (1998). Translating research into practice: the Schiozphrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24, 1–10.
Lenior, M. E., Dingemans, P. M., Schene, A. H., Hart, A. A., & Linszen, D. H. (2002). The course of parental expressed emotion and psychotic episodes after family intervention in recent-onset schizophrenia. A longitudinal study. Schizophrenia Research, 57, 183–190.
Leonard, S., Adams, C., Breese, C. R., Adler, L. E., Bickford, P., Byerley, W., et al. (1996). Nicotinic receptor function in schizophrenia. Schizophrenia Bulletin22, 431–445.
Leonard, S. C., Gault, J., Hopkins, J., Logel, J., Vianzon, R., Short, M., et al (2002). Association of promoter variants in the alpha 7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Archives of General Psychiatry, 59, 1085–1096.
Leucht, S., McGrath, J., White, P., & Kissling, W. (2002). Carbamazepine augmentation for schizophrenia: How good is the evidence? Journal of Clinical Psychiatry, 63, 218–224.
Lewis, C. M., Levinson, D. F., Wise, L. H., Delisi, L., Straub, R. E., Hovatta, I., et al. (2003). Genome scan meta-analysis of schizophrenia and bipolar disorder, Part II: Schizophrenia. American Journal of Human Genetics.
Lewis, R. (1998). Typical and atypical antipsychotics in adolescent schizophrenia: Efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Canadian Journal of Psychiatry, 43, 596–604.
Lewis, S., Tarrier, N., Haddock, G., Bentall, R., Kinderman, P., Kingdon, D., et al. (2002). Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. British Journal of Psychiatry, 43, s91–97.
Liddle, P. (1987). The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. British Journal of Psychiatry, 151, 145–151.
Lieberman, J. A. (1996). Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. Journal of Clinical Psychiatry, 57, 68–71.
Lieberman, J. A., Alvir, J. M., Koreen, A., Geisler, S., Chakos, M., Sheitman, B., et al. (1996). Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology, 14, 13S–21S.
end p.663
|
|
|
|
